Kaplan-Meier survival curves suggested that in the chemotherapy-only group, AML patients with high expressions of either ACTN1 or ACTN3 had shorter EFS and OS compared with patients with low expressions (p=0.002 for EFS, p=0.003 for OS, Figure 2A and 2B). Here, ACTN3 is linked to acute myeloid leukemia.